- Home
- GLDD vs ETNB Comparison
GLDD vs ETNB Comparison
Compare GLDD & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDD
- ETNB
- Stock Information
- Founded
- GLDD 1890
- ETNB 2018
- Country
- GLDD United States
- ETNB United States
- Employees
- GLDD N/A
- ETNB N/A
- Industry
- GLDD Military/Government/Technical
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- GLDD Industrials
- ETNB Health Care
- Exchange
- GLDD Nasdaq
- ETNB Nasdaq
- Market Cap
- GLDD 829.6M
- ETNB 933.6M
- IPO Year
- GLDD 2006
- ETNB 2019
- Fundamental
- Price
- GLDD $11.64
- ETNB $7.94
- Analyst Decision
- GLDD Buy
- ETNB Buy
- Analyst Count
- GLDD 1
- ETNB 7
- Target Price
- GLDD $14.00
- ETNB $30.33
- AVG Volume (30 Days)
- GLDD 408.4K
- ETNB 1.3M
- Earning Date
- GLDD 02-12-2025
- ETNB 11-07-2024
- Dividend Yield
- GLDD N/A
- ETNB N/A
- EPS Growth
- GLDD N/A
- ETNB N/A
- EPS
- GLDD 0.87
- ETNB N/A
- Revenue
- GLDD $741,648,000.00
- ETNB N/A
- Revenue This Year
- GLDD $33.01
- ETNB N/A
- Revenue Next Year
- GLDD $6.88
- ETNB N/A
- P/E Ratio
- GLDD $13.34
- ETNB N/A
- Revenue Growth
- GLDD 33.74
- ETNB N/A
- 52 Week Low
- GLDD $6.55
- ETNB $6.43
- 52 Week High
- GLDD $12.89
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- GLDD 40.95
- ETNB 47.30
- Support Level
- GLDD $11.30
- ETNB $6.43
- Resistance Level
- GLDD $11.97
- ETNB $8.10
- Average True Range (ATR)
- GLDD 0.41
- ETNB 0.53
- MACD
- GLDD -0.12
- ETNB -0.01
- Stochastic Oscillator
- GLDD 21.38
- ETNB 72.95
About GLDD Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).